Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

821
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
821
T Cell Types and Functions01:24

T Cell Types and Functions

3.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

47
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
47
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

14.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Targeted interleukin-6 blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers.

Frontiers in immunology·2026
Same author

Is the MAPK ERK5 the nexus from FAO to NK cell-mediated metastasis immune surveillance?

Frontiers in immunology·2025
Same author

Early diagnostic value of carotid artery ultrasound parameters combined with epicardial adipose layer thickness in coronary heart disease.

World journal of clinical cases·2024
Same author

Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer.

Cancer biology & medicine·2024
Same author

Dapagliflozin Suppresses Isoprenaline-Induced Cardiac Hypertrophy Through Inhibition of Mitochondrial Fission.

Journal of cardiovascular pharmacology·2023
Same author

Correction: Angiotensin-(1-9) prevents Angiotensin II-induced endothelial apoptosis through CNPY2/PERK pathway.

Apoptosis : an international journal on programmed cell death·2023

Related Experiment Video

Updated: Apr 18, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.5K

Interleukin-6 as a therapeutic target.

Jean-François Rossi1, Zhao-Yang Lu2, Michel Jourdan3

  • 1Department of Hematology, CHU de Montpellier, Montpellier, France. INSERM U1040, Montpellier, France. Université Montpellier I, Montpellier, France. jeanfrancoisrossi@me.com.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 16, 2015
PubMed
Summary

Interleukin-6 (IL6) inhibitors effectively treat inflammatory conditions like rheumatoid arthritis and Castleman disease by reducing inflammation. However, these therapies show limited efficacy in cancers due to cancer cell plasticity and existing treatment strategies.

More Related Videos

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
06:29

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

27.1K
Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

10.1K

Related Experiment Videos

Last Updated: Apr 18, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.5K
Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
06:29

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

27.1K
Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

10.1K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Interleukin-6 (IL6) is a cytokine with diverse roles, implicated in inflammation, anemia, and angiogenesis.
  • Anti-IL6 therapies, including monoclonal antibodies (mAbs) targeting IL6 or IL6 receptor (IL6R), are approved for Castleman disease and rheumatoid arthritis.
  • C-reactive protein (CRP) inhibition serves as a reliable efficacy marker for anti-IL6 treatments.

Purpose of the Study:

  • To evaluate the efficacy of anti-IL6 therapies in various cancers.
  • To understand the reasons behind the lack of efficacy in certain cancers despite IL6's known involvement.
  • To summarize the therapeutic potential and limitations of IL6 inhibition.

Main Methods:

  • Review of clinical trial data for anti-IL6 therapies in inflammatory diseases and cancers.
  • Analysis of C-reactive protein (CRP) inhibition as a surrogate marker.
  • Investigation into cancer cell plasticity and alternative growth factor utilization.

Main Results:

  • Anti-IL6 therapy demonstrates significant efficacy and safety in Castleman disease and rheumatoid arthritis.
  • Despite complete CRP inhibition, IL6 inhibitors failed to show efficacy in large randomized trials for plasma cell cancers.
  • Cancer cell plasticity and existing therapeutic strategies targeting IL6 contribute to treatment failure in cancers.

Conclusions:

  • Anti-IL6 therapeutics are valuable for inflammatory conditions and Castleman disease.
  • The efficacy of IL6 inhibitors in cancer is limited by tumor cell adaptability and pre-existing therapeutic interventions.
  • Further research may be needed to overcome resistance mechanisms in IL6-targeted cancer therapy.